Provided by Tiger Trade Technology Pte. Ltd.

Kodiak Sciences Inc.

38.33
-1.5100-3.79%
Post-market: 38.330.00000.00%19:30 EDT
Volume:509.12K
Turnover:19.77M
Market Cap:2.40B
PE:-9.22
High:40.90
Open:40.39
Low:37.99
Close:39.84
52wk High:47.84
52wk Low:8.29
Shares:62.58M
Float Shares:40.29M
Volume Ratio:0.83
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1571
EPS(LYR):-4.3220
ROE:-368.37%
ROA:-60.45%
PB:39.26
PE(LYR):-8.87

Loading ...

Kodiak Sciences Inc : Jefferies Raises Target Price to $56 From $39

THOMSON REUTERS
·
Mar 27

Meta, Kodiak Sciences, Unity Software, Lumentum Holdings And Reddit: Why These 5 Stocks Are On Investors' Radars Today

Benzinga
·
Mar 27

Kodiak Sciences Up Over 74%, on Pace for Record Percent Increase -- Data Talk

Dow Jones
·
Mar 27

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Kodiak Sciences (KOD)

TIPRANKS
·
Mar 27

Kodiak Sciences price target raised to $56 from $39 at Jefferies

TIPRANKS
·
Mar 27

BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan

Reuters
·
Mar 26

Wall Street Digests Fading Middle East Peace Prospects as US Equity Futures Decline Pre-Bell

MT Newswires Live
·
Mar 26

Kodiak Sciences Shares Surge 40% Premarket After Eye Drug Succeeds in Late-Stage Study

THOMSON REUTERS
·
Mar 26

Top Premarket Gainers

MT Newswires Live
·
Mar 26

Kodiak Sciences Says Tarcocimab Tedromer Shows 'Superiority' in Diabetic Retinopathy Phase 3 Trial

MT Newswires Live
·
Mar 26

Kodiak Sciences Shares Climb on Positive Late-Stage Trial Results

Dow Jones
·
Mar 26

Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham

Reuters
·
Mar 26

Kodiak Sciences Inc: Zenkuda Also Demonstrated Superiority to Sham With an 85% Risk Reduction in Key Secondary Endpoint

THOMSON REUTERS
·
Mar 26

Kodiak Sciences Inc: We Intend to Accelerate Our Bla Submission Plans

THOMSON REUTERS
·
Mar 26

Kodiak: Zenkuda Demonstrated Favorable Safety,Well Tolerated in Study With 0% Intraocular Inflammation Rate and 2.3% Cataract Adverse Event Rate

THOMSON REUTERS
·
Mar 26

Kodiak Sciences Inc: Zenkuda Demonstrated Strong Efficacy Independent of Concomitant Glp-1 Receptor Agonist Use

THOMSON REUTERS
·
Mar 26

Kodiak Sciences Announces Positive Topline Results in Glow2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (Tarcocimab Tedromer) Over Sham

THOMSON REUTERS
·
Mar 26

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Kodiak Sciences Inc expected to post a loss of $1.03 a share - Earnings Preview

Reuters
·
Mar 24

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 20